Skip to main content

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.

Publication ,  Journal Article
Pederson, AW; Salama, JK; Haraf, DJ; Witt, ME; Stenson, KM; Portugal, L; Seiwert, T; Villaflor, VM; Cohen, EEW; Vokes, EE; Blair, EA
Published in: Head Neck Oncol
July 26, 2011

BACKGROUND: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. METHODS: From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m² on d1), infusional 5-fluorouracil (600 mg/m²/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. RESULTS: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). CONCLUSIONS: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.

Duke Scholars

Published In

Head Neck Oncol

DOI

EISSN

1758-3284

Publication Date

July 26, 2011

Volume

3

Start / End Page

31

Location

England

Related Subject Headings

  • Treatment Outcome
  • Salivary Gland Neoplasms
  • Paclitaxel
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Hydroxyurea
  • Humans
  • Fluorouracil
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pederson, A. W., Salama, J. K., Haraf, D. J., Witt, M. E., Stenson, K. M., Portugal, L., … Blair, E. A. (2011). Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol, 3, 31. https://doi.org/10.1186/1758-3284-3-31
Pederson, Aaron W., Joseph K. Salama, Daniel J. Haraf, Mary Ellen Witt, Kerstin M. Stenson, Louis Portugal, Tanguy Seiwert, et al. “Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.Head Neck Oncol 3 (July 26, 2011): 31. https://doi.org/10.1186/1758-3284-3-31.
Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26;3:31.
Pederson, Aaron W., et al. “Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.Head Neck Oncol, vol. 3, July 2011, p. 31. Pubmed, doi:10.1186/1758-3284-3-31.
Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EEW, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26;3:31.

Published In

Head Neck Oncol

DOI

EISSN

1758-3284

Publication Date

July 26, 2011

Volume

3

Start / End Page

31

Location

England

Related Subject Headings

  • Treatment Outcome
  • Salivary Gland Neoplasms
  • Paclitaxel
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Hydroxyurea
  • Humans
  • Fluorouracil
  • Female